论文部分内容阅读
目的探讨分析利妥昔单抗联合CHOP方案治疗弥漫大B细胞淋巴瘤的临床疗效。方法 60例弥漫大B细胞淋巴瘤患者,随机分成观察组和对照组,各30例。观察组采取利妥昔单抗联合CHOP方案治疗,对照组采取单纯CHOP方案治疗,观察两组患者的临床疗效和不良反应。结果观察组总有效率明显高于对照组(P<0.05);两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论采用利妥昔单抗联合CHOP方案治疗弥漫大B细胞淋巴瘤疗效显著、不良反应少,值得广大医师在临床上应用推广。
Objective To investigate the clinical efficacy of rituximab combined with CHOP regimen in the treatment of diffuse large B cell lymphoma. Methods Sixty patients with diffuse large B-cell lymphoma were randomly divided into observation group and control group, with 30 cases in each group. The observation group was treated with rituximab combined with CHOP regimen. The control group was treated with simple CHOP regimen, and the clinical efficacy and adverse reactions were observed in both groups. Results The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Rituximab combined with CHOP regimen for the treatment of diffuse large B cell lymphoma significant effect, fewer adverse reactions, it is worth the majority of physicians in the clinical application and promotion.